These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 3625258)

  • 81. Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma.
    Dauer LT; St Germain J; Williamson MJ; Zanzonico P; Modak S; Cheung NK; Divgi C
    Health Phys; 2007 Jan; 92(1):33-9. PubMed ID: 17164597
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
    Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
    Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Intravenous lidocaine: effects on controlling pain after anti-GD2 antibody therapy in children with neuroblastoma--a report of a series.
    Wallace MS; Lee J; Sorkin L; Dunn JS; Yaksh T; Yu A
    Anesth Analg; 1997 Oct; 85(4):794-6. PubMed ID: 9322457
    [No Abstract]   [Full Text] [Related]  

  • 84. Cell-surface ganglioside GD2 in the immunohistochemical detection and differential diagnosis of neuroblastoma.
    Sariola H; Terävä H; Rapola J; Saarinen UM
    Am J Clin Pathol; 1991 Aug; 96(2):248-52. PubMed ID: 1713742
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma.
    Kremens B; Hero B; Esser J; Weinel P; Filger-Brillinger J; Fleischhack G; Graf N; Grüttner HP; Niemeyer C; Schulz A; Wickmann L; Berthold F
    Cancer Immunol Immunother; 2002 Apr; 51(2):107-10. PubMed ID: 11904735
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD
    Ceylan K; Jahns LJ; Lode BN; Ehlert K; Kietz S; Troschke-Meurer S; Siebert N; Lode HN
    Pediatr Blood Cancer; 2018 Jun; 65(6):e26967. PubMed ID: 29350486
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial.
    Cheung IY; Mauguen A; Modak S; Ragupathi G; Basu EM; Roberts SS; Kushner BH; Cheung NK
    JAMA Oncol; 2023 Feb; 9(2):242-250. PubMed ID: 36547975
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo.
    Cheung NK; Guo H; Hu J; Tassev DV; Cheung IY
    Oncoimmunology; 2012 Jul; 1(4):477-486. PubMed ID: 22754766
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-
    Modak S; Kushner BH; Kramer K; Vickers A; Cheung IY; Cheung NK
    Oncoimmunology; 2013 Mar; 2(3):e23402. PubMed ID: 23802080
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients.
    Uttenreuther-Fischer MM; Huang CS; Reisfeld RA; Yu AL
    Cancer Immunol Immunother; 1995 Jul; 41(1):29-36. PubMed ID: 7641217
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Impact of minimal tumor burden on antibody response to vaccination.
    Kim SK; Wu X; Ragupathi G; Gathuru J; Koide F; Cheung NK; Panageas K; Livingston PO
    Cancer Immunol Immunother; 2011 May; 60(5):621-7. PubMed ID: 21267719
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8.
    Kramer K; Cheung NK; Humm JL; Dantis E; Finn R; Yeh SJ; Antunes NL; Dunkel IJ; Souwedaine M; Larson SM
    Med Pediatr Oncol; 2000 Dec; 35(6):716-8. PubMed ID: 11107154
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse.
    Raffaghello L; Marimpietri D; Pagnan G; Pastorino F; Cosimo E; Brignole C; Ponzoni M; Montaldo PG
    Cancer Lett; 2003 Jul; 197(1-2):205-9. PubMed ID: 12880983
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Application of the murine anti-Gd-2 antibody 14.Gd-2a for diagnosis and therapy of neuroblastoma.
    Reuland P; Handgretinger R; Smykowsky H; Dopfer R; Klingebiel T; Miller BM; Reisfeld RA; Gallagher S; Koscelniak E; Treuner J
    Int J Rad Appl Instrum B; 1991; 18(1):121-5. PubMed ID: 2010296
    [TBL] [Abstract][Full Text] [Related]  

  • 95. GD2-targeted immunotherapy and radioimmunotherapy.
    Dobrenkov K; Cheung NK
    Semin Oncol; 2014 Oct; 41(5):589-612. PubMed ID: 25440605
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.
    Cheung IY; Cheung NV; Modak S; Mauguen A; Feng Y; Basu E; Roberts SS; Ragupathi G; Kushner BH
    J Clin Oncol; 2021 Jan; 39(3):215-226. PubMed ID: 33326254
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Targeted radiotherapy and immunotherapy of human neuroblastoma with GD2 specific monoclonal antibodies.
    Cheung NK; Munn D; Kushner BH; Usmani N; Yeh SD
    Int J Rad Appl Instrum B; 1989; 16(2):111-20. PubMed ID: 2497088
    [No Abstract]   [Full Text] [Related]  

  • 98. Shedding of GD2 ganglioside by human neuroblastoma.
    Ladisch S; Wu ZL; Feig S; Ulsh L; Schwartz E; Floutsis G; Wiley F; Lenarsky C; Seeger R
    Int J Cancer; 1987 Jan; 39(1):73-6. PubMed ID: 3539825
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Dinutuximab: first global approval.
    Dhillon S
    Drugs; 2015 May; 75(8):923-7. PubMed ID: 25940913
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial.
    Grant SC; Kostakoglu L; Kris MG; Yeh SD; Larson SM; Finn RD; Oettgen HF; Cheung NV
    Eur J Nucl Med; 1996 Feb; 23(2):145-9. PubMed ID: 8925848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.